Cargando…

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Detalles Bibliográficos
Autores principales:	Dhodapkar, Kavita, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott, Kluger, Harriet, Dhodapkar, Madhav, Das, Rituparna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288370/ http://dx.doi.org/10.1186/2051-1426-2-S3-O7

Ejemplares similares

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis
por: Dhodapkar, Kavita, et al.
Publicado: (2015)

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
por: Dhodapkar, Kavita M, et al.
Publicado: (2013)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
por: Costa, Federica, et al.
Publicado: (2018)

Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade
por: Dhodapkar, Kavita M.
Publicado: (2018)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
por: Dellepiane, Chiara, et al.
Publicado: (2015)

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
por: Dhodapkar, Madhav V., et al.
Publicado: (2019)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
por: McCachren, Samuel S., et al.
Publicado: (2021)

Conditional overexpression of TGFβ1 promotes pulmonary inflammation, apoptosis and mortality via TGFβR2 in the developing mouse lung
por: Sureshbabu, Angara, et al.
Publicado: (2015)

Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
por: Dhodapkar, Kavita M., et al.
Publicado: (2002)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
por: Su, David, et al.
Publicado: (2023)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
por: Safaeifard, Fateme, et al.
Publicado: (2022)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
por: Wei, Spencer C., et al.
Publicado: (2019)

A survey-wide association study to identify youth-specific correlates of major depressive episodes
por: Dhodapkar, Rahul Madhav
Publicado: (2020)

Enhancement of clonogenicity of human multiple myeloma by dendritic cells
por: Kukreja, Anjli, et al.
Publicado: (2006)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
por: Stamatouli, Angeliki M., et al.
Publicado: (2018)

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
por: Velcheti, Vamsidhar, et al.
Publicado: (2013)

The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
por: Maruoka, Yasuhiro, et al.
Publicado: (2020)

Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
por: Marable, Jonathan, et al.
Publicado: (2021)

Adoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression
por: Yee, Cassian, et al.
Publicado: (2014)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d43bud40cgcb168jgkqi2nmpbb